Apollomics, Inc.

NASDAQ:APLM

Biotechnology

Healthcare
$17.84 +34.72%

+$6.03 today

Market cap
$52.00M
Beta
1.45
P/E (TTM)
-3.1
EPS (TTM)
-$25.98
52W Low $3.66High $42.12

Volume 0.02M

Average 0.02M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$10.37M

FY 2025 · Annual

Investing Cash Flow

$218,000.00

FY 2025 · Annual

-96.4% YoY

Financing Cash Flow

$3.68M

FY 2025 · Annual

+685.5% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(94.8M)(240.81M)(172.59M)(53.6M)(10.94M)
Depreciation & Amortization681K775K669K361K255K
Deferred Income Tax00000
Stock-Based Compensation8.12M3.58M12.69M10.93M(979K)
Change in Working Capital2.64M6.49M(3.57M)1.04M(380K)
Accounts Receivables00000
Inventory00000
Accounts Payables00000
Other Working Capital2.64M6.49M(3.57M)1.04M(380K)
Other Non-Cash Items40.04M187.14M119.6M12.53M1.67M
Operating Cash Flow(43.31M)(42.82M)(43.21M)(28.74M)(10.37M)
Capital Expenditures(7.55M)(367K)(6K)(24K)0
Acquisitions (Net)00000
Purchases of Investments(103.79M)0000
Sales of Investments71.95M29M20.49M5.76M0
Other Investing Activities(7.06M)420K884K246K218K
Investing Cash Flow(38.95M)29.05M21.37M5.98M218K
Debt Repayment(528K)(593K)24.04M661K3.73M
Common Stock Issued141K392K85K07K
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(1.26M)(93K)(2.9M)(193K)(65K)
Financing Cash Flow(1.64M)(294K)21.23M468K3.68M
Effect of Forex Changes0002K(15K)
Net Change in Cash(83.91M)(14.07M)(619K)(22.29M)(6.49M)
Free Cash Flow(50.86M)(43.19M)(43.22M)(28.77M)(10.37M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$10.9M
+ D&A$255.0K
+ Stock-Based Comp-$979.0K
+ Deferred Tax$0
- Working Capital-$380.0K
+ Other Non-Cash$1.7M
= Operating Cash Flow-$10.4M
- Capex$0
= Free Cash Flow-$10.4M

Analysis

FY2025 free cash flow is -$10.4M. FCF conversion is 94.8% of net income. Operating cash flow was -$10.4M, with capex of $0. The largest bridge item is Other Non-Cash at $1.7M.

Competitors

Peer companies in the same sector

Health

Recent Filings

Recent regulatory filings

FilingDescriptionDate
6-K6-K filingNov 6, 2026
4/A4/A filingSep 24, 2026
4/A4/A filingSep 24, 2026
4/A4/A filingSep 24, 2026
4Statement of changes in beneficial ownershipSep 17, 2026

Does APLM generate free cash flow?

Apollomics, Inc. (APLM) generated -$10.37M of free cash flow in fiscal 2025.

How much operating cash flow does APLM produce?

Operating cash flow was -$10.37M, before capital expenditures of $0.00.